Work

9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)

Year: 2009

Type: conference-abstract

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(09)71871-3

Authors: F. Cappuzzo, B. Coudert, R. Wierzbicki, K. Park, F. Custers, G.A. Curbera, G. Giaccone, W. Hilbe, G. Klingelschmitt, T. Ciuleanu

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2015446090

Cites:

Cited by: 7

Related to: 10